Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 80
- Registration Number
- NCT00703976
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Study of Cetuximab to Treat Gastric Cancer
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 61
- Registration Number
- NCT00699881
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 79
- Registration Number
- NCT00698841
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇺🇸Cancer Specialists Of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Lecia V. Sequist
- Target Recruit Count
- 56
- Registration Number
- NCT00694603
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 30
- Registration Number
- NCT00689624
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Greece
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 904
- Registration Number
- NCT00678535
- Locations
- 🇬🇧
Research site, Manchester, United Kingdom
🇨🇳Research Site, Taipei, Taiwan
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2015-10-08
- Target Recruit Count
- 27
- Registration Number
- NCT00673738
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT00671437
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸Washington University, St. Louis, Missouri, United States
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00671372
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2021-06-25
- Target Recruit Count
- 42
- Registration Number
- NCT00665392
- Locations
- 🇫🇷
Hopital Bichat - Claude Bernard, Paris, France
🇫🇷Hôpital Simone Veil, Montmorency, France
🇫🇷Hôpital Privé St Joseph, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.